FDA Brief

Warning letters Drugs

FDA warning letter to

Mahita LLC dba PushMyCart

High riskIssued Nov 17, 2025Posted Nov 25, 2025Center for Drug Evaluation and Research (CDER)

FDA told online seller PushMyCart its website and Facebook posts sell unapproved drugs claiming to treat measles, cancer, diabetes and Parkinson's.

What happened

FDA reviewed the website pushmycart.com in September 2025 and also looked at the company's Facebook account, which sends shoppers to that site. FDA found the products offered for sale with labeling claiming to cure, treat or prevent serious diseases such as measles, hepatitis, Parkinson's disease, diabetes, glaucoma and high blood pressure. FDA says none of the products has an approved drug application.

What FDA found

  1. The products are drugs because their labels say they diagnose, cure, treat or prevent disease, and FDA has not approved them for those uses.

    Section 505(a) of the FD&C Act, 21 U.S.C. 355(a)
  2. The products are 'new drugs' because they are not generally recognized as safe and effective for the uses on their labels.

    Section 201(p) of the FD&C Act, 21 U.S.C. 321(p)
  3. The website and Facebook posts show the products are meant to treat diseases, which makes them drugs under the law.

    Section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1); 21 CFR 201.128
  4. Shipping these unapproved drugs across state lines is illegal.

    Sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a)
  5. FDA is especially concerned about the glaucoma eye drop, because medicines put into the eye bypass some of the body's natural defenses.

  6. Calling a product homeopathic does not exempt it from the law; homeopathic drugs must still meet the same approval, misbranding and adulteration rules as other drugs.

    Section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1)

What FDA wants

FDA asks the company to write to CDER's Office of Unapproved Drugs and Labeling Compliance within fifteen working days, describing each step taken to fix the violations and to prevent them from happening again. If corrections cannot be finished in that time, the company must say why and give a completion date.

Who should pay attention

  • online marketplaces and e-commerce platforms hosting supplement or homeopathic listings
  • retailers and distributors that stock homeopathic or Ayurvedic products
  • brands whose products are resold on third-party websites

This is a summary. Read the original letter on fda.gov.

Mahita LLC dba PushMyCart's FDA history

  1. Mahita, LLC dba PushMyCart

    FDA and FTC warn Mahita/PushMyCart over unapproved Ayurvedic/homeopathic COVID-19 treatment claims.

    High risk

Full company page

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk